Pharmaceutical preparations, namely, oral, small-molecule, anti-copper agent that is highly specific for lowering the levels of free copper in serum; reducing toxic free copper levels and substantially improve clinical outcomes in neurologically-presenting Wilson's disease patients; treatment for fibrotic disorders, including idiopathic pulmonary fibrosis, based upon the rationale that the fibrotic disease process is dependent upon the availability of endogenous free copper; possible treatmen...